SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North American Neuroendocrine Tumor Society (NANETS) annual meeting, highlighting major advances in its neuroendocrine tumor (NET) programs. The company presented one-year progression-free survival (PFS) data of 74% from a Phase 2 trial evaluating Paltusotine, an oral SST2 agonist, in patients with carcinoid syndrome. Crinetics also revealed preclinical progress for CRN09682, its novel non-peptide drug conjugate (NDC) targeting SST2-expressing tumors. Together, these programs demonstrate the company’s growing clinical footprint in endocrine-related oncology.
Science Significance
The data represent a pivotal step in precision endocrinology-oncology research. Paltusotine, already approved for acromegaly, is being explored for carcinoid syndrome linked to NETs. The reported 74% one-year PFS indicates a potentially strong anti-tumor effect in a population with limited treatment options. Meanwhile, CRN09682—a non-peptide drug conjugate combining an SST2 agonist with a cytotoxic payload (MMAE)—is designed to selectively destroy tumor cells while reducing systemic toxicity. This dual-approach strategy, spanning receptor agonism and targeted cytotoxic delivery, exemplifies Crinetics’ scientific innovation in next-generation NET therapeutics.
Regulatory Significance
Presenting these findings at NANETS provides critical regulatory visibility for Crinetics’ clinical development. Paltusotine’s prior approval in acromegaly strengthens the case for label expansion into carcinoid syndrome, potentially streamlining its FDA review process. The company’s preparation for a Phase 3 CAREFNDR trial and first-in-human studies for CRN09682 indicate readiness to align with regulatory pathways for rare diseases. This progress supports broader policy goals of accelerating innovation in underserved oncology indications.
Business Significance
Advertisement
From a strategic perspective, these results reinforce Crinetics’ position as a clinical-stage biopharmaceutical leader in endocrine and neuroendocrine disorders. Demonstrating meaningful PFS outcomes expands its addressable market beyond hormone disorders into oncology. The dual-track advancement of Paltusotine and CRN09682 enhances pipeline depth and investor confidence. With growing validation of its small-molecule and conjugate platforms, Crinetics strengthens its potential for strategic partnerships, commercial collaborations, and future revenue growth driven by rare tumor indications.
Patients’ Significance
For patients living with carcinoid syndrome and neuroendocrine tumors, treatment options are often limited and primarily symptom-focused. The oral dosing of Paltusotine offers a more convenient alternative to injectable therapies, while the NDC candidate aims to provide tumor-targeted precision therapy with fewer side effects. If Phase 3 results confirm the early efficacy seen in Phase 2, these therapies could significantly delay disease progression, improve quality of life, and reduce treatment burden for patients with these rare malignancies.
Policy Significance
The Crinetics program aligns with policy priorities promoting innovation in rare cancer research, accelerated approval pathways, and precision medicine. Regulatory agencies continue to encourage industry collaboration for orphan indications, and Crinetics’ progress exemplifies how data transparency and clinical rigor can advance that mission. By participating in major scientific meetings and sharing robust data, the company supports global policy efforts focused on expanding therapeutic access in rare oncology populations.
Crinetics’ 2025 NANETS presentations signal a transformative moment in neuroendocrine tumor treatment. The company’s 74% one-year PFS milestone for Paltusotine and the advancement of CRN09682 highlight its strength in translational clinical innovation. As Crinetics advances toward Phase 3 trials and regulatory milestones, it stands poised to redefine standards of care in neuroendocrine oncology, bringing new hope to patients and fresh energy to the clinical biopharma landscape.
Source: Crinetics Pharmaceuticals, Inc. press release
